Effect  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
Adenoviral  ||| S:10 E:21 ||| NNP
Catalase  ||| S:21 E:30 ||| NNP
Gene  ||| S:30 E:35 ||| NNP
Transfer  ||| S:35 E:44 ||| NNP
on  ||| S:44 E:47 ||| IN
Renal  ||| S:47 E:53 ||| NNP
Ischemia ||| S:53 E:61 ||| NNP
/ ||| S:61 E:62 ||| NNP
Reperfusion  ||| S:62 E:74 ||| NNP
Injury  ||| S:74 E:81 ||| NNP
in  ||| S:81 E:84 ||| IN
Rats  ||| S:84 E:89 ||| NNP
Ischemia ||| S:89 E:97 ||| NNP
/ ||| S:97 E:98 ||| FW
reperfusion  ||| S:98 E:110 ||| FW
( ||| S:110 E:111 ||| -LRB-
I ||| S:111 E:112 ||| NNP
/ ||| S:112 E:113 ||| NNP
R ||| S:113 E:114 ||| NNP
)  ||| S:114 E:116 ||| -RRB-
may  ||| S:116 E:120 ||| MD
through  ||| S:120 E:128 ||| RB
overt  ||| S:128 E:134 ||| CD
H₂O₂-induced  ||| S:134 E:147 ||| CD
pathophysiologic  ||| S:147 E:164 ||| CD
mechanisms  ||| S:164 E:175 ||| NNS
lead  ||| S:175 E:180 ||| VBP
to  ||| S:180 E:183 ||| TO
renal  ||| S:183 E:189 ||| JJ
dysfunction ||| S:189 E:200 ||| NN
.  ||| S:200 E:202 ||| .
We  ||| S:202 E:205 ||| PRP
explore  ||| S:205 E:213 ||| VB
whether  ||| S:213 E:221 ||| IN
catalase  ||| S:221 E:230 ||| NNS
( ||| S:230 E:231 ||| -LRB-
CAT ||| S:231 E:234 ||| NNP
)  ||| S:234 E:236 ||| -RRB-
protein  ||| S:236 E:244 ||| NN
overexpression  ||| S:244 E:259 ||| NN
by  ||| S:259 E:262 ||| IN
adenoviral  ||| S:262 E:273 ||| JJ
CAT  ||| S:273 E:277 ||| NNP
gene  ||| S:277 E:282 ||| NN
( ||| S:282 E:283 ||| -LRB-
Adv-CAT ||| S:283 E:290 ||| NNP
)  ||| S:290 E:292 ||| -RRB-
transfection  ||| S:292 E:305 ||| NN
may  ||| S:305 E:309 ||| MD
improve  ||| S:309 E:317 ||| VB
ischemia ||| S:317 E:325 ||| FW
/ ||| S:325 E:326 ||| FW
reperfusion-induced  ||| S:326 E:346 ||| FW
renal  ||| S:346 E:352 ||| FW
dysfunction ||| S:352 E:363 ||| FW
.  ||| S:363 E:365 ||| .
We  ||| S:365 E:368 ||| PRP
augmented  ||| S:368 E:378 ||| VBP
renal  ||| S:378 E:384 ||| JJ
CAT  ||| S:384 E:388 ||| NNP
expression  ||| S:388 E:399 ||| NN
by  ||| S:399 E:402 ||| IN
intrarenal  ||| S:402 E:413 ||| JJ
arterial  ||| S:413 E:422 ||| JJ
Adv-CAT  ||| S:422 E:430 ||| JJ
administration  ||| S:430 E:445 ||| NN
with  ||| S:445 E:450 ||| IN
renal  ||| S:450 E:456 ||| JJ
venous  ||| S:456 E:463 ||| JJ
clamping  ||| S:463 E:472 ||| NN
in  ||| S:472 E:475 ||| IN
avertin-anesthetized  ||| S:475 E:496 ||| JJ
female  ||| S:496 E:503 ||| JJ
Wistar  ||| S:503 E:510 ||| JJ
rats ||| S:510 E:514 ||| NNS
.  ||| S:514 E:516 ||| .
After  ||| S:516 E:522 ||| IN
Adv-CAT  ||| S:522 E:530 ||| JJ
transfection ||| S:530 E:542 ||| NN
,  ||| S:542 E:544 ||| ,
we  ||| S:544 E:547 ||| PRP
examined  ||| S:547 E:556 ||| VBD
the  ||| S:556 E:560 ||| DT
CAT  ||| S:560 E:564 ||| NNP
expression ||| S:564 E:574 ||| NN
,  ||| S:574 E:576 ||| ,
location  ||| S:576 E:585 ||| NN
and  ||| S:585 E:589 ||| CC
effects  ||| S:589 E:597 ||| NNS
on  ||| S:597 E:600 ||| IN
blood  ||| S:600 E:606 ||| NN
urea  ||| S:606 E:611 ||| NN
nitrogen  ||| S:611 E:620 ||| NNS
( ||| S:620 E:621 ||| -LRB-
BUN ||| S:621 E:624 ||| NNP
)  ||| S:624 E:626 ||| -RRB-
and  ||| S:626 E:630 ||| CC
urinary  ||| S:630 E:638 ||| JJ
tubular  ||| S:638 E:646 ||| JJ
injury  ||| S:646 E:653 ||| NN
biomarkers  ||| S:653 E:664 ||| NN
by  ||| S:664 E:667 ||| IN
biochemical  ||| S:667 E:679 ||| JJ
assays ||| S:679 E:685 ||| NN
,  ||| S:685 E:687 ||| ,
microcirculation  ||| S:687 E:704 ||| VBG
by  ||| S:704 E:707 ||| IN
a  ||| S:707 E:709 ||| DT
laser  ||| S:709 E:715 ||| NN
perfusion  ||| S:715 E:725 ||| NN
imager ||| S:725 E:731 ||| NN
,  ||| S:731 E:733 ||| ,
renal  ||| S:733 E:739 ||| JJ
H₂O₂  ||| S:739 E:744 ||| CD
amount  ||| S:744 E:751 ||| NN
by  ||| S:751 E:754 ||| IN
a  ||| S:754 E:756 ||| DT
chemiluminescent  ||| S:756 E:773 ||| JJ
analyzer  ||| S:773 E:782 ||| NN
and  ||| S:782 E:786 ||| CC
molecular  ||| S:786 E:796 ||| JJ
mechanisms  ||| S:796 E:807 ||| NNS
including  ||| S:807 E:817 ||| VBG
cytosolic  ||| S:817 E:827 ||| NNS
cytochrome  ||| S:827 E:838 ||| VBD
C  ||| S:838 E:840 ||| $
leakage ||| S:840 E:847 ||| CD
,  ||| S:847 E:849 ||| ,
apoptosis ||| S:849 E:858 ||| NN
,  ||| S:858 E:860 ||| ,
autophagy  ||| S:860 E:870 ||| NN
and  ||| S:870 E:874 ||| CC
phospho-  ||| S:874 E:883 ||| NNP
Akt  ||| S:883 E:887 ||| NNP
( ||| S:887 E:888 ||| -LRB-
p-Akt ||| S:888 E:893 ||| NNP
) ||| S:893 E:894 ||| -RRB-
/ ||| S:894 E:895 ||| FW
phospho-endothelial  ||| S:895 E:915 ||| FW
nitric  ||| S:915 E:922 ||| FW
oxide  ||| S:922 E:928 ||| FW
( ||| S:928 E:929 ||| -LRB-
p-eNOS ||| S:929 E:935 ||| NNP
) ||| S:935 E:936 ||| -RRB-
/ ||| S:936 E:937 ||| FW
nitric  ||| S:937 E:944 ||| FW
oxide  ||| S:944 E:950 ||| FW
( ||| S:950 E:951 ||| -LRB-
NO ||| S:951 E:953 ||| UH
)  ||| S:953 E:955 ||| -RRB-
signaling  ||| S:955 E:965 ||| VBG
by  ||| S:965 E:968 ||| IN
western  ||| S:968 E:976 ||| JJ
blotting ||| S:976 E:984 ||| NN
,  ||| S:984 E:986 ||| ,
immunohistochemistry  ||| S:986 E:1007 ||| NN
and  ||| S:1007 E:1011 ||| CC
immunofluorescence ||| S:1011 E:1029 ||| NN
.  ||| S:1029 E:1031 ||| .
Adv-CAT  ||| S:1031 E:1039 ||| FW
enhanced  ||| S:1039 E:1048 ||| FW
2.6-fold  ||| S:1048 E:1057 ||| FW
renal  ||| S:1057 E:1063 ||| FW
CAT  ||| S:1063 E:1067 ||| NNP
protein  ||| S:1067 E:1075 ||| NN
expression  ||| S:1075 E:1086 ||| NN
primarily  ||| S:1086 E:1096 ||| RB
located  ||| S:1096 E:1104 ||| VBN
in  ||| S:1104 E:1107 ||| IN
the  ||| S:1107 E:1111 ||| DT
proximal  ||| S:1111 E:1120 ||| NN
and  ||| S:1120 E:1124 ||| CC
distal  ||| S:1124 E:1131 ||| JJ
tubules  ||| S:1131 E:1139 ||| NN
and  ||| S:1139 E:1143 ||| CC
renal  ||| S:1143 E:1149 ||| JJ
vessels ||| S:1149 E:1156 ||| NNS
.  ||| S:1156 E:1158 ||| .
Ischemia ||| S:1158 E:1166 ||| FW
/ ||| S:1166 E:1167 ||| FW
reperfusion  ||| S:1167 E:1179 ||| FW
increased  ||| S:1179 E:1189 ||| FW
cytosolic  ||| S:1189 E:1199 ||| FW
cytochrome  ||| S:1199 E:1210 ||| FW
C  ||| S:1210 E:1212 ||| NNP
leakage ||| S:1212 E:1219 ||| NN
,  ||| S:1219 E:1221 ||| ,
renal  ||| S:1221 E:1227 ||| JJ
H₂O₂-dependent  ||| S:1227 E:1242 ||| CD
level ||| S:1242 E:1247 ||| NN
,  ||| S:1247 E:1249 ||| ,
autophagic  ||| S:1249 E:1260 ||| FW
Beclin-1 ||| S:1260 E:1268 ||| FW
/ ||| S:1268 E:1269 ||| FW
Atg5-Atg12 ||| S:1269 E:1279 ||| FW
/ ||| S:1279 E:1280 ||| FW
LC3  ||| S:1280 E:1284 ||| FW
II  ||| S:1284 E:1287 ||| NNP
expression ||| S:1287 E:1297 ||| NN
,  ||| S:1297 E:1299 ||| ,
apoptotic  ||| S:1299 E:1309 ||| VBG
Bax ||| S:1309 E:1312 ||| NNP
/ ||| S:1312 E:1313 ||| CD
Bcl-2 ||| S:1313 E:1318 ||| CD
/ ||| S:1318 E:1319 ||| CD
caspase  ||| S:1319 E:1327 ||| CD
3 ||| S:1327 E:1328 ||| CD
/ ||| S:1328 E:1329 ||| CD
poly- ||| S:1329 E:1334 ||| NNS
( ||| S:1334 E:1335 ||| -LRB-
ADP-ribose ||| S:1335 E:1345 ||| NNP
) ||| S:1345 E:1346 ||| -RRB-
-polymerase  ||| S:1346 E:1358 ||| JJ
fragments  ||| S:1358 E:1368 ||| NNS
( ||| S:1368 E:1369 ||| -LRB-
PARP ||| S:1369 E:1373 ||| NNP
)  ||| S:1373 E:1375 ||| -RRB-
expression  ||| S:1375 E:1386 ||| NN
and  ||| S:1386 E:1390 ||| CC
terminal  ||| S:1390 E:1399 ||| FW
deoxynucleotidyl  ||| S:1399 E:1416 ||| FW
transferasemediated  ||| S:1416 E:1436 ||| FW
nick-end  ||| S:1436 E:1445 ||| FW
labeling  ||| S:1445 E:1454 ||| FW
( ||| S:1454 E:1455 ||| -LRB-
TUNEL ||| S:1455 E:1460 ||| NNP
)  ||| S:1460 E:1462 ||| -RRB-
stains  ||| S:1462 E:1469 ||| NNS
and  ||| S:1469 E:1473 ||| CC
BUN  ||| S:1473 E:1477 ||| NNP
and  ||| S:1477 E:1481 ||| CC
urinary  ||| S:1481 E:1489 ||| FW
glutathione  ||| S:1489 E:1501 ||| FW
S-transferase  ||| S:1501 E:1515 ||| FW
( ||| S:1515 E:1516 ||| -LRB-
GST ||| S:1516 E:1519 ||| NNP
)  ||| S:1519 E:1521 ||| -RRB-
levels  ||| S:1521 E:1528 ||| NNS
leading  ||| S:1528 E:1536 ||| VBG
to  ||| S:1536 E:1539 ||| TO
proximal  ||| S:1539 E:1548 ||| VB
tubular  ||| S:1548 E:1556 ||| JJ
injury ||| S:1556 E:1562 ||| NN
.  ||| S:1562 E:1564 ||| .
Ischemia ||| S:1564 E:1572 ||| NNP
/ ||| S:1572 E:1573 ||| NNP
reperfusion  ||| S:1573 E:1585 ||| VBD
also  ||| S:1585 E:1590 ||| RB
decreased  ||| S:1590 E:1600 ||| VBD
renal  ||| S:1600 E:1606 ||| JJ
microvascular  ||| S:1606 E:1620 ||| JJ
blood  ||| S:1620 E:1626 ||| NN
flow  ||| S:1626 E:1631 ||| NN
associated  ||| S:1631 E:1642 ||| VBN
with  ||| S:1642 E:1647 ||| IN
the  ||| S:1647 E:1651 ||| DT
inhibited  ||| S:1651 E:1661 ||| JJ
renal  ||| S:1661 E:1667 ||| JJ
expression  ||| S:1667 E:1678 ||| NN
of  ||| S:1678 E:1681 ||| IN
p-Akt  ||| S:1681 E:1687 ||| JJ
and  ||| S:1687 E:1691 ||| CC
p-eNOS  ||| S:1691 E:1698 ||| JJ
and  ||| S:1698 E:1702 ||| CC
NO  ||| S:1702 E:1705 ||| DT
production ||| S:1705 E:1715 ||| NN
.  ||| S:1715 E:1717 ||| .
Adv-CAT  ||| S:1717 E:1725 ||| NNP
significantly  ||| S:1725 E:1739 ||| RB
improved  ||| S:1739 E:1748 ||| VBN
the  ||| S:1748 E:1752 ||| DT
reduction  ||| S:1752 E:1762 ||| NN
in  ||| S:1762 E:1765 ||| IN
renal  ||| S:1765 E:1771 ||| JJ
microvascular  ||| S:1771 E:1785 ||| JJ
blood  ||| S:1785 E:1791 ||| NN
flow ||| S:1791 E:1795 ||| NN
,  ||| S:1795 E:1797 ||| ,
reduced  ||| S:1797 E:1805 ||| VBD
ischemia ||| S:1805 E:1813 ||| CD
/ ||| S:1813 E:1814 ||| CD
reperfusion-enhanced  ||| S:1814 E:1835 ||| JJ
oxidative  ||| S:1835 E:1845 ||| JJ
stress ||| S:1845 E:1851 ||| NN
,  ||| S:1851 E:1853 ||| ,
Beclin-1 ||| S:1853 E:1861 ||| FW
/ ||| S:1861 E:1862 ||| FW
Atg5-Atg12 ||| S:1862 E:1872 ||| FW
/ ||| S:1872 E:1873 ||| FW
LC3  ||| S:1873 E:1877 ||| FW
II-meidated  ||| S:1877 E:1889 ||| FW
autophagy ||| S:1889 E:1898 ||| FW
,  ||| S:1898 E:1900 ||| ,
Bax ||| S:1900 E:1903 ||| NNP
/ ||| S:1903 E:1904 ||| CD
Bcl-2 ||| S:1904 E:1909 ||| CD
/ ||| S:1909 E:1910 ||| CD
caspase  ||| S:1910 E:1918 ||| CD
3 ||| S:1918 E:1919 ||| CD
/ ||| S:1919 E:1920 ||| CD
PARP-mediated  ||| S:1920 E:1934 ||| JJ
apoptotic  ||| S:1934 E:1944 ||| JJ
signaling ||| S:1944 E:1953 ||| NN
,  ||| S:1953 E:1955 ||| ,
TUNEL  ||| S:1955 E:1961 ||| NNP
stains ||| S:1961 E:1967 ||| NNS
,  ||| S:1967 E:1969 ||| ,
urinary  ||| S:1969 E:1977 ||| JJ
GST  ||| S:1977 E:1981 ||| NNP
level ||| S:1981 E:1986 ||| NN
,  ||| S:1986 E:1988 ||| ,
and  ||| S:1988 E:1992 ||| CC
restored  ||| S:1992 E:2001 ||| VBD
the  ||| S:2001 E:2005 ||| DT
p-Akt ||| S:2005 E:2010 ||| JJ
/ ||| S:2010 E:2011 ||| NNP
p-eNOS ||| S:2011 E:2017 ||| NNP
/ ||| S:2017 E:2018 ||| NNP
NO  ||| S:2018 E:2021 ||| RB
signaling  ||| S:2021 E:2031 ||| VBG
in  ||| S:2031 E:2034 ||| IN
the  ||| S:2034 E:2038 ||| DT
kidney ||| S:2038 E:2044 ||| NN
.  ||| S:2044 E:2046 ||| .
Treatment  ||| S:2046 E:2056 ||| NN
of  ||| S:2056 E:2059 ||| IN
phosphatidylinositol  ||| S:2059 E:2080 ||| CD
3-kinase  ||| S:2080 E:2089 ||| CD
inhibitors ||| S:2089 E:2099 ||| NN
,  ||| S:2099 E:2101 ||| ,
wortmannin  ||| S:2101 E:2112 ||| NN
and  ||| S:2112 E:2116 ||| CC
LY294002 ||| S:2116 E:2124 ||| NNP
,  ||| S:2124 E:2126 ||| ,
deleted  ||| S:2126 E:2134 ||| FW
Adv-CAT-induced  ||| S:2134 E:2150 ||| FW
p-Akt ||| S:2150 E:2155 ||| FW
/ ||| S:2155 E:2156 ||| FW
p-eNOS ||| S:2156 E:2162 ||| FW
/ ||| S:2162 E:2163 ||| FW
NO  ||| S:2163 E:2166 ||| FW
protective  ||| S:2166 E:2177 ||| FW
signaling ||| S:2177 E:2186 ||| FW
.  ||| S:2186 E:2188 ||| .
In  ||| S:2188 E:2191 ||| IN
conclusion ||| S:2191 E:2201 ||| NN
,  ||| S:2201 E:2203 ||| ,
our  ||| S:2203 E:2207 ||| PRP$
results  ||| S:2207 E:2215 ||| NNS
suggest  ||| S:2215 E:2223 ||| VBP
Adv-CAT  ||| S:2223 E:2231 ||| JJ
gene  ||| S:2231 E:2236 ||| NN
transfer  ||| S:2236 E:2245 ||| NN
counteracts  ||| S:2245 E:2257 ||| FW
H₂O₂-induced  ||| S:2257 E:2270 ||| FW
ischemia ||| S:2270 E:2278 ||| FW
/ ||| S:2278 E:2279 ||| FW
reperfusion  ||| S:2279 E:2291 ||| FW
injury  ||| S:2291 E:2298 ||| FW
through  ||| S:2298 E:2306 ||| FW
preserving  ||| S:2306 E:2317 ||| FW
p-Akt ||| S:2317 E:2322 ||| FW
/ ||| S:2322 E:2323 ||| FW
p-eNOS ||| S:2323 E:2329 ||| FW
/ ||| S:2329 E:2330 ||| FW
NO  ||| S:2330 E:2333 ||| DT
pathway  ||| S:2333 E:2341 ||| NN
in  ||| S:2341 E:2344 ||| IN
the  ||| S:2344 E:2348 ||| DT
rat  ||| S:2348 E:2352 ||| JJ
kidney ||| S:2352 E:2358 ||| NN
.  ||| S:2358 E:2360 ||| .
